Risks of Private Testosterone Prescribing Cited by BMJ Experts

Growth in Private Prescribing and Market Scale

Private clinics are expanding commercial hormone services across the United Kingdom. This growth raises specific concerns regarding the risks of private testosterone prescribing for borderline health conditions. In an analysis for The British Medical Journal (BMJ), Stephen Atkin and Eric Kilpatrick report that commercial programs charge £100 to £375 monthly.

These subscription packages bundle remote consultations, home-delivered hormones, and regular monitoring. The market is growing fast. Industry valuations estimated the domestic sector at $205 million in 2024, with forecasts reaching $365 million by 2032. National Health Service (NHS) community dispensing climbed 52% from 2020/21 to 2024/25. Private prescription volumes remain unrecorded. Heavy marketing across social media and outdoor billboards accelerates sales.

Diagnostic Limits and the Risks of Private Testosterone Prescribing

Commercial subscription models often fail to handle the diagnostic complexities required to confirm hormone deficiency. Circulating testosterone and sexual desire decline naturally as people grow older. Up to one-fifth of men over 50 report deficiency symptoms. Yet under 1% receive treatment through the NHS.

Accurate clinical diagnosis requires multiple blood evaluations conducted over several weeks. Online clinics often bypass repeated testing. Instead, private providers frequently apply permissive thresholds that contradict standard professional society guidelines, exposing patients to unneeded lifelong interventions.

Clinical Risks of Private Testosterone Prescribing in Long-Term Care

Prolonged testosterone therapy carries documented risks to the cardiovascular system and renal function that necessitate continuous medical monitoring. Commercial providers rarely supply the extensive follow-up needed for chronic treatment. Public systems absorb the fallout.

Hospital clinicians routinely evaluate patients who initiated hormone regimens through private clinics without adequate baseline screening. Managing complications from private overtreatment strains public resources. Commercial clinics collect monthly subscription fees while leaving complications to public services.

Shared Care Gaps and Off-Label Prescribing for Women

Private prescribers retain full legal responsibility for patient care unless an NHS General Practitioner (GP) signs a formal agreement. Few formal shared-care agreements exist. Patients often consult their GP informally to obtain blood tests or manage unexpected side effects. This informal transfer shifts work to public family doctors without proper clinical coordination.

Similar patterns appear in off-label private prescriptions for women experiencing menopausal low libido. Community records show a tenfold rise in testosterone gel prescriptions for English women aged 50 and older between 2015 and 2022. Unregulated private prescribing leaves doctors without data on total exposure.

Addressing the Risks of Private Testosterone Prescribing through Oversight

Testosterone replacement therapy offers clear therapeutic value for individuals with verified clinical deficiency. The authors do not advocate stopping appropriate treatment. They recommend establishing a mandatory national reporting framework for private prescribers and dispensing pharmacies.

This registry would record clinical indications, patient numbers, monitoring schedules, and formal transfers of care. Transparent recording ensures private clinics adhere to evidence-based standards while protecting patient safety. Anyone considering hormone therapy should discuss the risks of private testosterone prescribing with an NHS GP before starting commercial treatment.